Your browser is no longer supported. Please, upgrade your browser.
BioVie Inc.
Index- P/E- EPS (ttm)-16.50 Insider Own79.70% Shs Outstand15.80M Perf Week0.39%
Market Cap196.56M Forward P/E- EPS next Y-5.32 Insider Trans0.00% Shs Float4.93M Perf Month-0.65%
Income-183.80M PEG- EPS next Q- Inst Own1.50% Short Float5.51% Perf Quarter-54.60%
Sales- P/S- EPS this Y-116.30% Inst Trans13.97% Short Ratio4.39 Perf Half Y-62.02%
Book/sh0.32 P/B24.03 EPS next Y-3.30% ROA- Target Price- Perf Year-21.13%
Cash/sh0.18 P/C43.68 EPS next 5Y- ROE- 52W Range7.11 - 46.10 Perf YTD-55.60%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-83.30% Beta2.26
Dividend %- Quick Ratio4.60 Sales past 5Y- Gross Margin- 52W Low8.30% ATR0.42
Employees2 Current Ratio4.60 Sales Q/Q- Oper. Margin- RSI (14)36.67 Volatility5.10% 5.49%
OptionableNo Debt/Eq0.00 EPS Q/Q-125.90% Profit Margin- Rel Volume1.30 Prev Close7.69
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume61.89K Price7.70
Recom2.00 SMA20-0.83% SMA50-26.62% SMA200-57.25% Volume77,172 Change0.13%
Jan-15-21Initiated B. Riley Securities Buy $47
Sep-22-21 08:00AM  
Sep-15-21 04:01PM  
Aug-11-21 01:14PM  
Aug-08-21 09:28PM  
Aug-06-21 05:30PM  
Aug-05-21 08:00AM  
Jul-27-21 08:00AM  
Jul-22-21 08:00AM  
Jul-16-21 08:00AM  
Jun-29-21 08:00AM  
Jun-28-21 08:00AM  
Jun-25-21 08:00AM  
Jun-24-21 08:00AM  
Jun-23-21 08:00AM  
Jun-17-21 04:05PM  
Jun-11-21 08:00AM  
May-12-21 08:00AM  
May-10-21 08:19AM  
Apr-28-21 07:00AM  
Apr-27-21 04:05PM  
Mar-11-21 07:00AM  
Mar-09-21 07:00AM  
Feb-19-21 07:00AM  
Feb-02-21 08:30AM  
Oct-30-20 08:00AM  
Oct-29-20 08:00AM  
Sep-23-20 08:00AM  
Sep-21-20 07:00AM  
Sep-17-20 07:55PM  
Jun-16-20 08:30AM  
Jun-11-20 08:30AM  
Dec-09-19 08:00AM  
Oct-22-19 07:00AM  
BioVie Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of drugs therapies in the United States. It develops BIV201, which completed Phase 2a clinical trial for the treatment of ascites due to chronic liver cirrhosis. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was founded in 2013 and is based in Santa Monica, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
GORLIN STEVEDirectorNov 03Buy7.952,43019,31845,100Dec 15 03:01 PM
GORLIN STEVEDirectorOct 30Buy7.972,57020,48342,670Dec 15 03:00 PM
GORLIN STEVEDirectorOct 21Buy9.195,00045,95040,100Oct 22 03:10 PM
GORLIN STEVEDirectorOct 15Buy10.195,10051,96725,100Oct 19 02:59 PM
GORLIN STEVEDirectorOct 15Buy10.0510,000100,55035,100Oct 19 02:59 PM
GORLIN STEVEDirectorOct 09Buy9.612822,71020,000Oct 14 02:07 PM
GORLIN STEVEDirectorOct 07Buy9.424,71844,44419,718Oct 14 02:05 PM